View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
December 15, 2021updated 07 Jan 2022 5:58am

Coronavirus company news summary – Oravax begins enrolment for oral Covid-19 vaccine trial in South Africa – Moderna’s Covid-19 vaccine secures marketing approval in South Korea

By Darcy Jimenez

Oravax Medical, a subsidiary of Oramed Pharmaceuticals, has enrolled the first participant for Phase I clinical trial of its oral virus-like particle Covid-19 vaccine in South Africa. The company aims to enrol 24 participants who are yet to receive a vaccine or have contracted the disease. During the trial, two doses of the vaccine will be administered at a gap of three weeks. The study endpoints include assessing the safety and tolerability of the vaccine as well as determining its efficacy.

Moderna’s Covid-19 vaccine Spikevax (mRNA-1273) has secured marketing authorisation in South Korea. The vaccine is manufactured by Samsung Biologics under a previously signed agreement with Moderna. The approval, granted by the Ministry of Food and Drug Safety of Korea, will enable Moderna to distribute the vaccine manufactured in Samsung Biologics’ local facilities across South Korea. It will also enable the company to export Spikevax to other countries.

Malaysia’s health ministry has granted conditional approval for the use of Ronapreve in Covid-19 treatment, reported The Star. The single-dose antibody cocktail, developed by Roche and Regeneron, was indicated for treating individuals above 12 years of age and at risk of developing severe infection. It was further added that Ronapreve can be administered as an injection or infusion in patients who weigh at least 40kg and do not require supplemental oxygen.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology